| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 7,192.1 | 6,644.8 | 6,219.3 | 6,059.17 | 5,963.88 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 7,192.1 | 6,644.8 | 6,219.3 | 6,059.17 | 5,963.88 |
Other Operating Income | 42.4 | 58.1 | 62.4 | 70.99 | 134.66 |
Other Income | 416.3 | 92.8 | 50.6 | 11.29 | 290.64 |
Total Income | 7,650.8 | 6,795.7 | 6,332.3 | 6,141.45 | 6,389.18 |
Total Expenditure | 6,061.3 | 5,971 | 5,562.3 | 4,983.81 | 4,723.3 |
PBIDT | 1,589.5 | 824.7 | 770 | 1,157.64 | 1,665.88 |
Interest | 240.3 | 272.3 | 188.2 | 145.49 | 184.1 |
PBDT | 1,349.2 | 552.4 | 581.8 | 1,012.15 | 1,481.78 |
Depreciation | 368.6 | 381.9 | 554 | 381.7 | 348.95 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 213.2 | 202.6 | 181.1 | 172.55 | 269.91 |
Deferred Tax | -68.9 | -104.8 | -88.4 | 44.88 | 27.31 |
Reported Profit After Tax | 836.3 | 72.7 | -64.9 | 413.02 | 835.61 |
Minority Interest After NP | -3.1 | -4.4 | -3.9 | -0.92 | -0.26 |
Net Profit after Minority Interest | 839.4 | 77.1 | -61 | 413.94 | 835.87 |
Extra-ordinary Items | 281.34 | 31.8 | 124.3 | 0 | -13.99 |
Adjusted Profit After Extra-ordinary item | 558.06 | 45.3 | -185.3 | 413.94 | 849.86 |
EPS (Unit Curr.) | 52.99 | 4.87 | -3.83 | 26 | 52.48 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 500 | 500 | 500 | 500 | 500 |
Equity | 15.8 | 15.8 | 15.9 | 15.92 | 15.92 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 22.1 | 12.41 | 12.38 | 19.1 | 27.93 |
PBDTM(%) | 18.75 | 8.31 | 9.35 | 16.7 | 24.84 |
PATM(%) | 11.62 | 1.09 | -1.04 | 6.81 | 14.01 |
The API division posted a turnover of ₹609 Crore for the financial year ended March 2025. This was 8.35% of the company’s consolidated revenue.
Here are some of the stocks that may see significant price movement today: Torrent Power, DCM Shriram, Jubilant Pharmova, etc.
This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.
Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.
Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
